Claims
- 1. A composition comprising:(A) at least one active agent; and (B) a compound having the following formula or a salt thereof.
- 2. A composition as defined in claim 1, wherein said active agent is selected from the group consisting of a biologically active agent, a chemically active agent, and a combination thereof.
- 3. A composition as defined in claim 2, wherein said biologically active agent comprises at least one peptide, hormone, polysaccharide, mucopolysaceharide, carbohydrate, or lipid.
- 4. The composition as defined in claim 3, wherein said biologically active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, parathyroid hormone, desferrioxamine, an anti-microbial agent, an anti-fungal agent, and any combination thereof.
- 5. A composition as defined in claim 4, wherein said biologically active agent comprises an interferon, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, oxytocin, vasopressin, vancomycin, DFO, parathyroid hormone, or a combination thereof.
- 6. A composition as defined in claim 2, wherein said biologically active agent comprises parathyroid hormone.
- 7. A composition as defined in claim 2, wherein said biologically active agent comprises recombinant human growth hormone.
- 8. A composition as defined on claim 2, wherein said biologically active agent comprises interferon.
- 9. A composition as defined in claim 2, wherein said biologically active agent comprises heparin.
- 10. A composition as defined in claim 2, wherein said biologically active agent comprises low molecular weight heparin.
- 11. A composition as defined in claim 1, wherein said compound comprises a poly(amino acid).
- 12. A composition as defined in claim 1, wherein said compound comprises a polypeptide.
- 13. A dosage unit form comprising:(A) a composition as defined in claim 1; and (B) (a) an excipient (b) a diluent, (c) a disintegrant, (d) a lubricant, (e) a plasticizer, (f) a colorant, (g) a dosing vehicle, or (h) any combination thereof.
- 14. The dosage unit form as defined in claim 13, wherein said active agent is selected from the group consisting of a biologically active agent, a chemically active agent, and a combination thereof.
- 15. The dosage unit form as defined in claim 14, wherein said biologically active agent comprises at least one peptide, hormone, polysaceharide, mucopolysaccharide, carbohydrate, or lipid.
- 16. The dosage unit form as defined in claim 15, wherein said biologically active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-1, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vaneomycin, parathyroid hormone, desferrioxamine, an anti-microbial agent, an anti-fungal agent, and any combination thereof.
- 17. A dosage unit form as defined in claim 16, wherein said biologically active agent comprises an interferon, interleukin-II, insulin, heparin, low molecular weight heparin, calcitonin, oxytocin, vasopressin, vancomycin, DFO, parathyroid hormone, or a combination thereof.
- 18. A dosage unit form as defined in claim 14, wherein said biologically active agent comprises parathyroid hormone.
- 19. A dosage unit form as defined in claim 14, wherein said biologically active agent comprises recombinant human growth hormone.
- 20. A dosage unit form as defined on claim 14, wherein said biologically active agent comprises interferon.
- 21. A dosage unit form as defined in claim 14, wherein said biologically active agent comprises heparin.
- 22. A dosage unit form as defined in claim 14, wherein said biologically active agent comprises low molecular weight heparin.
- 23. A dosage unit form as defined in claim 13, comprising a tablet, a capsule, or a liquid.
- 24. A dosage unit form as defined in claim 23, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol, and any combination thereof.
- 25. A method for administering a biologically-active agent to an animal in need of said agent, said method comprising administering orally to said animal a composition as defined in claim 2.
- 26. A compound having the formula or a salt thereof.
- 27. A method for preparing a composition, said method comprising mixing:(A) at least one active agent; (B) at least one compound as defined in claim 26; and (C) optionally, a dosing vehicle.
- 28. A composition comprising:(A) at least one active agent; and (B) a poly(amino acid) comprising a monomer having the formula or a salt thereof.
- 29. A composition as defined in claim 28, wherein the poly(amino acid) comprises a peptide.
Parent Case Info
This application is a continuation of application Ser. No. 09/499,958, filed Feb. 8, 2000, now U.S. Pat. No. 6,346,242, which in turn is a continuation of application Ser. No. 09/305,506, filed May 5, 1999, now U.S. Pat. No. 6,428,780, which is a continuation of Ser. No. 08/798,031, filed Feb. 6, 1997, now U.S. Pat. No. 6,001,347, which is a continuation of PCT application No. PCT/US 96/04580, filed Apr. 1, 1996, published as International Publication No. WO 96/30036, which is a continuation-in-part of application Ser. No. 08/414,654, filed Mar. 31, 1995, now U.S. Pat. No. 5,650,386, and claims benefit to application Ser. No. 60/003,111, filed Sep. 1, 1995 and application Ser. No. 60/017,902, filed Mar. 29, 1996. Each of these prior applications is hereby incorporated herein by reference, in its entirety.
US Referenced Citations (63)
Foreign Referenced Citations (15)
Number |
Date |
Country |
0036145 |
Sep 1981 |
EP |
226223 |
Jun 1987 |
EP |
0365183 |
Apr 1990 |
EP |
0517211 |
Dec 1992 |
EP |
0576941 |
Jan 1994 |
EP |
369853 |
Jul 1971 |
ES |
2095994 |
Oct 1982 |
GB |
2239980 |
Sep 1990 |
JP |
9747270 |
Dec 1997 |
WO |
8807378 |
Oct 1998 |
WO |
0006184 |
Feb 2000 |
WO |
0006534 |
Feb 2000 |
WO |
0007979 |
Feb 2000 |
WO |
0009390 |
Feb 2000 |
WO |
0048589 |
Aug 2000 |
WO |
Non-Patent Literature Citations (17)
Entry |
Picciola G.: “Sintesi Di Acidi Chiazolinioici E Benzossazinonici E Studio Delle Loro Proprieta Antiniammatorie” IT, Societa Chimica Italiana Pavia vol. 31, No. 9 pp. 655-664 and English Translation (1976). |
Chem Abs 73548-12-6 (Apr. 1991). |
Chem Abs 70204-54-5 (Apr. 1991). |
Chem Abs 184360-83-342 (1975) Solubility and disassociation constants of some alicyclic acids. |
Chemical Abstract, vol. 99(23) Abst. No 191473h (1983). |
Riveria, Theresa M. et al. “Oral Delivery of Heparin in Combination with Sodium N-[8-2-hydroxybenzoyl)amino]caprylate: Pharmacological Considerations” Pharmaceutical Research vol. 14(12) 1830-1834 (1997). |
Leone-Bay, A. et al. “The evolution of an oral heparin dosing solution” Drugs of the Future vol. 22(8) 885-891 (1997). |
Brayden, D. et al. “Heparin Absorption across the intestin: Effects of Sodium N-[8-2hydorxybenzoyl)Amino] Caprylate in rat in situ intestinal instillations ind in Caco-2 monolayers” Pharmaceutical Research vol. 14(12) 1772-1779 (1997). |
Leone-Bay, A. “Acylated non-alpha-amino acids as novle agents for the oral delivery of heparin sodium, USP” Journal of Controlled Release 50: 41-49 (1998). |
Leone-Bay, A. “4-[4-(2-Hydroxybenzoyl)amino]phenyl]-butyric Acid as Novel Oral Delivery Agent for Recombinant Human Growth Hormone”; Journal of Medicinal Chemistry vol. 39, No. 13 pp. 2571-2578 (1996). |
Leone-Bay, A. “N-Acylated alpha-amino acids as novel oral delivery agents for proteins”; Journal of Medicinal Chemistry vol. 38, 4263-4269 (1995). |
Leone-Bay, A. “N-Acylated alpha-amino acids as novel oral delivery agents for proteins”; Journal of Medicinal Chemistry vol. 38, 4257-4262 (1995). |
Ho Koc-Kan; et al. “A Practical Synthesis of ω-aminoalkanopic acid derivatives form Cycloalkanones” Synthetic Communication, vol. 26, No. 14: 2641-2649 (1996). |
Gurrieri and Siracusa: “Thermal Condensation of Some alpha-aminoacids with Phatalic Acid” Thermochimica Acta, 7(1973) 231-239. |
Amino Yusuke et al. Chem Pharm Bull 36 pp. 4426-4434 (1988). |
Brown et al., J. Med. Chem. 27:79-81 (1984). |
Johansen, Marianne, et al. “The Kinetics of decompn. Of various N-Mannich bases of salicylamide” Int. J. Pharm. (1980), 7(2): 119-127 (1980). |
Provisional Applications (2)
|
Number |
Date |
Country |
|
60/003111 |
Sep 1995 |
US |
|
60/017902 |
Mar 1996 |
US |
Continuations (4)
|
Number |
Date |
Country |
Parent |
09/499958 |
Feb 2000 |
US |
Child |
10/038426 |
|
US |
Parent |
09/305506 |
May 1999 |
US |
Child |
09/499958 |
|
US |
Parent |
08/798031 |
Feb 1997 |
US |
Child |
09/305506 |
|
US |
Parent |
PCT/US96/04580 |
Apr 1996 |
US |
Child |
08/798031 |
|
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
08/414654 |
Mar 1995 |
US |
Child |
PCT/US96/04580 |
|
US |